Categories: Health

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2024 and corporate updates, before market open, on Tuesday, November 12, 2024.

Company to Host Conference Call
Members of the Company’s leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, November 12, 2024.

Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at http://ir.optinose.com/event-calendar. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

GlobeNews Wire

Recent Posts

KFSHRC Madinahs Virtual Clinics Wins Award at PX Congress

RIYADH, Saudi Arabia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research…

6 hours ago

IBA Business Update Third Quarter 2024

Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in…

6 hours ago

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR…

6 hours ago

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

– Kura to receive a $330 million upfront payment and up to $1.2 billion in…

6 hours ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Revuforj (revumenib)

LOUISVILLE, Ky., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy,…

6 hours ago

Las Vegas Unveils Exclusive Entertainment, Packages and More for Race Week 2024

Destination Revving up This Year’s Excitement with Top-Tier Entertainment, Luxurious Trackside Experiences and Celebrations like…

9 hours ago